5096 results about "Agonist" patented technology

Disclosed in the present invention are a GLP-1 receptor agonist, and a preparation method therefor and a use thereof. Specifically, disclosed are a compound represented by formula (I), and a use thereof in preparation of a drug for treating or preventing GLP-1 receptor-mediated diseases.

The present invention relates to a system and method for providing adaptive digital therapy, enhancing the emotional well-being of users through the analysis and translation of expressive and physiological states. Aspects of the invention are directed to identifying the neuroplastic window via user inputs, with or without the aid of psychedelics. This invention is particularly suited for supporting psychoactive therapies involving compounds such as 5-HT2A agonists, dissociatives, and empathogens, as well as applications beyond psychoactive treatments. By utilizing multi-modal deep learning methods, the system captures a wide array of user inputs, including text, speech, vision, symbols, and brain waves, to form a dynamic user representation. This representation is then used to provide real-time, tailored generative communications informed by established psychological therapeutic frameworks. The invention features a closed-loop feedback system through an access module, enabling continuous data relay, patient response metric derivation, and transmission of emotional optimization communications. The system also introduces novel communication methods, including symbolic language input, to articulate complex experiences and extends its capabilities to include natural emotional states, broadening its therapeutic applicability.

A CHRM4 receptor agonist and the use thereof. Disclosed in the present invention are a compound as represented by formula (I), or a stereoisomer, a deuterated substance, a solvate, an eutectic or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, and the use thereof in the preparation of a drug for treating / preventing CHRM4-mediated diseases, wherein each group in formula (I) is as defined in the description.

A nitrogen-containing fused ring compound as a GLP-1 receptor agonist, and a preparation method therefor and the use thereof. Specifically, provided are a compound as represented by formula (I), and the use thereof in the preparation of a drug for treating or preventing diseases mediated by GLP-1.

The invention discloses a nitrogen-containing bridged ring compound serving as a GLP-1 receptor agonist as well as a preparation method and application of the nitrogen-containing bridged ring compound. Specifically, the invention discloses a compound as shown in a formula (I), and application of the compound in preparation of drugs for treating or preventing GLP-1 mediated diseases. # imgabs0 #

A long-acting injection preparation and a preparation method therefor. The preparation contains an active compound such as the compound as shown in formula (I) or formula (II), or compound 6, or a stereoisomer, pharmaceutically acceptable salt or deuterated compound thereof, and at least one pharmaceutically acceptable carrier.

The invention aims to provide a crystal form of a thyroid hormone receptor agonist, a preparation method, a pharmaceutical composition and application of the crystal form in preparation of a TRbeta selective agonist medicine. Compared with the prior art, the crystal form provided by the invention has one or more improved properties, and is of great significance to further development of the medicine.

The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.

A novel prodrug compound having GLP1R agonist activity. Specifically disclosed is a compound having a structure represented by formula (I) as a GLP1R agonist, or a pharmaceutically acceptable salt, solvate, hydrate, isotopic substituent or isomer thereof.

The invention relates to the technical field of medicines, in particular to a GLP-1 agonist as well as a preparation method and application thereof. The GLP-1 agonist has a structure as shown in a formula I, or a pharmaceutically acceptable salt or solvate thereof. The GLP-1 agonist provided by the invention has relatively high activity and bioavailability.

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.

Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

The invention provides a compound as shown in a formula I, or pharmaceutically acceptable salt, stereoisomer or tautomer thereof. The compounds have been demonstrated to be good GLP-1 receptor agonists. In addition, the compound is simple in preparation method and has a certain application prospect. # imgabs0 #

The present application relates to a GLP-1 receptor agonist, which is a compound of formula (II) or a pharmaceutically acceptable salt thereof, and a method for treating or preventing a GLP-1 receptor-mediated disease or disorder or regulating a GLP-1 receptor.

Disclosed herein is a preserved liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist, a cyclodextrin comprising hydroxypropyl substitutions and one or more preservatives. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; and cardiovascular diseases.

A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and / or thrombopoietin receptor (TPO-R) agonists.

Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and / or prevention of diabetes.

The invention relates to a synthesis method of a GLP-1R agonist Orforglipron, and the synthesis method is as shown in the following formula. # imgabs0 #

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

Relating to a compound represented by formula (I) and a pharmaceutically acceptable salt of the compound, and an application of the compound as an S1P1 agonist.

The invention discloses a preparation method of a GLP-1R agonist Orforglipron, which comprises the following reaction steps: carrying out four-step reaction on an oxopiperidine compound (1) and (4-fluoro-3, 5-dimethylphenyl) hydrazine (2) to obtain a compound 8, and carrying out seven-step reaction on 5-bromo-indolecarboxylic acid (9) to obtain a compound 17. Then, the compound 8 and a compound 17 are subjected to an acid amine condensation reaction, and Orforglipron (LY3502970) is obtained. The preparation method is relatively low in cost, easy to operate, relatively short in synthetic route and suitable for industrial production and application, and the total yield can reach 32%.

The invention discloses sodium alginate hydrogel for extracting pesticide and veterinary drug COFs and application of the sodium alginate hydrogel, and belongs to the field of detection. According to the invention, seven COFs are designed and synthesized, including grafting of different functional groups, different charged properties and different conjugated structures, and then corresponding seven COFs-sodium alginate hydrogel (CACPs) are prepared, and the COFs-sodium alginate hydrogel (CACPs) is used as an extraction material of dSPE to be applied to detection of common pesticide and veterinary drugs. The adsorption capacity of the CACPs on pesticide and veterinary drugs is coordinated and determined by the porous structure properties (specific surface area and pore size) of the CACPs and the inherent structure (conjugate structure size and grafting group) of the loaded COFs. The CACPs prepared from the COFs with large conjugated structures and grafted hydroxyl groups are most beneficial to adsorption of carbamate pesticides; for triazole and triazine pesticides and sulfonamide antibiotics, the CACPs with large specific surface area and medium pore diameter has the best extraction effect; for beta-receptor agonists, the CACPs with a large specific surface area have the best extraction effect.